Antipsychotic  ||| S:0 E:14 ||| JJ
long-acting  ||| S:14 E:26 ||| JJ
injections ||| S:26 E:36 ||| NNS
:  ||| S:36 E:38 ||| :
mind  ||| S:38 E:43 ||| VB
the  ||| S:43 E:47 ||| DT
gap  ||| S:47 E:51 ||| NN
Long-acting  ||| S:51 E:63 ||| JJ
injections  ||| S:63 E:74 ||| NNS
of  ||| S:74 E:77 ||| IN
antipsychotic  ||| S:77 E:91 ||| JJ
medication  ||| S:91 E:102 ||| NN
( ||| S:102 E:103 ||| -LRB-
or  ||| S:103 E:106 ||| CC
depots ||| S:106 E:112 ||| NNS
)  ||| S:112 E:114 ||| -RRB-
were  ||| S:114 E:119 ||| VBD
developed  ||| S:119 E:129 ||| VBN
specifically  ||| S:129 E:142 ||| RB
to  ||| S:142 E:145 ||| TO
promote  ||| S:145 E:153 ||| VB
treatment  ||| S:153 E:163 ||| NN
adherence  ||| S:163 E:173 ||| NNS
and  ||| S:173 E:177 ||| CC
are  ||| S:177 E:181 ||| VBP
a  ||| S:181 E:183 ||| DT
valuable  ||| S:183 E:192 ||| JJ
option  ||| S:192 E:199 ||| NN
for  ||| S:199 E:203 ||| IN
maintenance  ||| S:203 E:215 ||| NN
medication  ||| S:215 E:226 ||| NN
in  ||| S:226 E:229 ||| IN
psychotic  ||| S:229 E:239 ||| JJ
illnesses ||| S:239 E:248 ||| NNS
.  ||| S:248 E:250 ||| .
Approximately  ||| S:250 E:264 ||| RB
40-60 ||| S:264 E:269 ||| CD
%  ||| S:269 E:271 ||| NN
of  ||| S:271 E:274 ||| IN
patients  ||| S:274 E:283 ||| NNS
with  ||| S:283 E:288 ||| IN
schizophrenia  ||| S:288 E:302 ||| NNS
are  ||| S:302 E:306 ||| VBP
partially  ||| S:306 E:316 ||| RB
or  ||| S:316 E:319 ||| CC
totally  ||| S:319 E:327 ||| RB
non-adherent  ||| S:327 E:340 ||| JJ
to  ||| S:340 E:343 ||| TO
their  ||| S:343 E:349 ||| PRP$
antipsychotic  ||| S:349 E:363 ||| JJ
regimen ||| S:363 E:370 ||| NN
,  ||| S:370 E:372 ||| ,
but  ||| S:372 E:376 ||| CC
only  ||| S:376 E:381 ||| RB
30 ||| S:381 E:383 ||| CD
%  ||| S:383 E:385 ||| NN
or  ||| S:385 E:388 ||| CC
less  ||| S:388 E:393 ||| JJR
are  ||| S:393 E:397 ||| VBP
prescribed  ||| S:397 E:408 ||| VBN
a  ||| S:408 E:410 ||| DT
long-acting  ||| S:410 E:422 ||| JJ
injection ||| S:422 E:431 ||| NN
.  ||| S:431 E:433 ||| .
The  ||| S:433 E:437 ||| DT
use  ||| S:437 E:441 ||| NN
of  ||| S:441 E:444 ||| IN
such  ||| S:444 E:449 ||| JJ
injections  ||| S:449 E:460 ||| NN
has  ||| S:460 E:464 ||| VBZ
declined  ||| S:464 E:473 ||| VBN
in  ||| S:473 E:476 ||| IN
recent  ||| S:476 E:483 ||| JJ
years  ||| S:483 E:489 ||| NNS
after  ||| S:489 E:495 ||| IN
the  ||| S:495 E:499 ||| DT
introduction  ||| S:499 E:512 ||| NN
of  ||| S:512 E:515 ||| IN
second-generation  ||| S:515 E:533 ||| NNP
( ||| S:533 E:534 ||| -LRB-
atypical ||| S:534 E:542 ||| LS
)  ||| S:542 E:544 ||| -RRB-
oral  ||| S:544 E:549 ||| JJ
antipsychotic  ||| S:549 E:563 ||| JJ
drugs ||| S:563 E:568 ||| NNS
.  ||| S:568 E:570 ||| .
Research  ||| S:570 E:579 ||| NNP
shows  ||| S:579 E:585 ||| VBZ
that  ||| S:585 E:590 ||| DT
possible  ||| S:590 E:599 ||| JJ
reasons  ||| S:599 E:607 ||| NNS
for  ||| S:607 E:611 ||| IN
this  ||| S:611 E:616 ||| DT
decline  ||| S:616 E:624 ||| NN
include  ||| S:624 E:632 ||| VBP
concerns  ||| S:632 E:641 ||| NNS
that  ||| S:641 E:646 ||| WDT
may  ||| S:646 E:650 ||| MD
be  ||| S:650 E:653 ||| VB
based  ||| S:653 E:659 ||| VBN
on  ||| S:659 E:662 ||| IN
suboptimal  ||| S:662 E:673 ||| JJ
knowledge ||| S:673 E:682 ||| NN
,  ||| S:682 E:684 ||| ,
as  ||| S:684 E:687 ||| RB
well  ||| S:687 E:692 ||| RB
as  ||| S:692 E:695 ||| IN
an  ||| S:695 E:698 ||| DT
erroneous  ||| S:698 E:708 ||| JJ
assumption  ||| S:708 E:719 ||| NN
that  ||| S:719 E:724 ||| IN
one ||| S:724 E:727 ||| NN
's  ||| S:727 E:730 ||| POS
own  ||| S:730 E:734 ||| JJ
patient  ||| S:734 E:742 ||| NN
group  ||| S:742 E:748 ||| NN
is  ||| S:748 E:751 ||| VBZ
more  ||| S:751 E:756 ||| JJR
adherent  ||| S:756 E:765 ||| NN
than  ||| S:765 E:770 ||| IN
those  ||| S:770 E:776 ||| DT
of  ||| S:776 E:779 ||| IN
one ||| S:779 E:782 ||| NN
's  ||| S:782 E:785 ||| POS
colleagues ||| S:785 E:795 ||| NNS
.  ||| S:795 E:797 ||| .
Research  ||| S:797 E:806 ||| NN
on  ||| S:806 E:809 ||| IN
attitudes  ||| S:809 E:819 ||| NNS
has  ||| S:819 E:823 ||| VBZ
also  ||| S:823 E:828 ||| RB
revealed  ||| S:828 E:837 ||| VBN
that  ||| S:837 E:842 ||| IN
psychiatrists  ||| S:842 E:856 ||| NNS
feel  ||| S:856 E:861 ||| VBP
that  ||| S:861 E:866 ||| IN
long-acting  ||| S:866 E:878 ||| JJ
injections  ||| S:878 E:889 ||| NNS
have  ||| S:889 E:894 ||| VBP
an  ||| S:894 E:897 ||| DT
; ||| S:897 E:898 ||| :
image ||| S:898 E:903 ||| NN
'  ||| S:903 E:905 ||| POS
problem ||| S:905 E:912 ||| NN
.  ||| S:912 E:914 ||| .
This  ||| S:914 E:919 ||| DT
editorial  ||| S:919 E:929 ||| NN
addresses  ||| S:929 E:939 ||| VBZ
the  ||| S:939 E:943 ||| DT
gaps  ||| S:943 E:948 ||| NN
in  ||| S:948 E:951 ||| IN
knowledge  ||| S:951 E:961 ||| NN
and  ||| S:961 E:965 ||| CC
behaviour  ||| S:965 E:975 ||| VB
associated  ||| S:975 E:986 ||| VBN
with  ||| S:986 E:991 ||| IN
possible  ||| S:991 E:1000 ||| JJ
underutilisation  ||| S:1000 E:1017 ||| NN
of  ||| S:1017 E:1020 ||| IN
these  ||| S:1020 E:1026 ||| DT
formulations ||| S:1026 E:1038 ||| NN
,  ||| S:1038 E:1040 ||| ,
highlighting  ||| S:1040 E:1053 ||| VBG
the  ||| S:1053 E:1057 ||| DT
role  ||| S:1057 E:1062 ||| NN
of  ||| S:1062 E:1065 ||| IN
stigma  ||| S:1065 E:1072 ||| NN
and  ||| S:1072 E:1076 ||| CC
the  ||| S:1076 E:1080 ||| DT
need  ||| S:1080 E:1085 ||| NN
for  ||| S:1085 E:1089 ||| IN
more  ||| S:1089 E:1094 ||| JJR
research ||| S:1094 E:1102 ||| NN
.  ||| S:1102 E:1104 ||| .
